Skip to Content
  • Rank41
  • Previous Rank42
  • CEO
    Alex Gorsky
  • Address
    1 Johnson & Johnson Plaza, New Brunswick, NJ 8933
  • Website
    www.jnj.com

After a rough few years for the multibillion-dollar pharmaceutical company –including recalls, lawsuits and a bruising management shakeup — Johnson & Johnson regained some momentum last year. The sprawling conglomerate still makes everything from baby powder to artificial hips. But most of J&J’s recent growth has been fueled by its pharmaceutical division, which makes the blockbuster drugs Remicade, for Crohn’s Disease and rheumatoid arthritis, and Stelara, immunology medication.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Key Financials

$ Millions% change
Revenues67,2243.4
Profits
10853.00
12.2
Assets121,347-
Total Shareholder Equity64,826-
Market Value (on March 29, 2013)227,902.4-

Profit as a % of

Profit Percent Sales227,902.4
Profit Percent Assets8.9
Profit Percent Shareholder Equity16.7

Earnings Per Share

Earnings Per Share3.86
EPS % Change (from 2012)10.6
EPS Change (5 year)1.2
EPS Change (10 year)6

Total Return to Investors

Total Return to Investors10.8
Total Return to Investors (5 year)4.4
Total Return to Investors (10 year)
5.50